Kornimate/medical-research-clean huggingface dataset:
sms system for patients with uncontrolled hypertension

Conditions: Hypertension

Summary: this is a pilot study to determine the potential of utilizing short message service (sms) messaging to improve health outcomes for patients with uncontrolled hypertension receiving care from the outpatient internal medicine clinic at wake forest baptist hospital.

the pilot will evaluate the feasibility of implementing a short message service (sms) system and home blood pressure measurements (hbpm) in the outpatient internal medicine (opd) clinic at wake forest baptist hospital. implementing a new short text messaging service will improve the health delivery system in three ways. 1) increasing patient engagement: sms and hbpm require an active commitment by the patients themselves in their medical care and results in a marked improvement in the adherence to medication. high adherence to home blood pressure (bp) measurements has also been reported to improve bp control. 2) supporting patients outside of the office visits by identifying and resolving barriers to medication adherence earlier on (i.e. if patients are unable to get their prescriptions or are having significant side effects). 3) adopting clinical guidelines to improve bp control in a vulnerable population.

Eligibility criteria:
inclusion criteria: * patients who have been diagnosed with hypertension * 18 and older * stage 2 hypertension or greater systolic blood pressure \[(sbp)\>140 and diastolic blood pressure (dbp) \>90\] who are receiving antihypertensive treatment. exclusion criteria: * pregnancy * end-stage renal disease (on hemodialysis or peritoneal dialysis) * hospice or nursing home care * dementia * patients who do not have a phone with short message service (sms) capabilities will also be excluded.

Keywords: high blood pressure sms text messaging monitoring
heart transplant patients, health status and physical activity

Conditions: Disease, Chronic

Summary: the aim of this cross-sectional observational study is (1) to assess the health status of a group of heart transplant patients and their level of physical activity, (2) and to compare the health status of a group of heart transplant patients with different levels of physical activity, with a group of healthy people classified as sedentary (due to their level of physical activity).


Eligibility criteria:
inclusion criteria: * heart transplant adults (18 years old) whose transplant had taken place at least twelve months before the study data was taken. * heart transplant patients with low, moderate and high levels of physical activity, according to the results of the international physical activity questionnaire - long form (ipaq-l). * healthy people with low levels of physical activity, according to the results of the international physical activity questionnaire - long form (ipaq-l). exclusion criteria: * do not meet the eligibility criteria. * have physical disabilities and/or other limiting pathologies that would condition their level of physical activity. * have participated in cardiac rehabilitation programs during the twelve months prior to the study.
electrical stimulation and vaginal palpation in pelvic floor muscles awareness

Conditions: Pelvic Floor Disorders

Summary: the purpose of this study is to evaluate the effectiveness of transvaginal electrical stimulation, vaginal palpation, and vaginal palpation associated with posterior pelvic tilt and contraction of accessory muscles in the acquisition of ability to contract the pelvic floor muscles (pfm), as well as to evaluate the sexual function of women studied.

many women does not know to contract the pfm voluntarily favoring the development of disorders such as urinary and fecal incontinence, pelvic organ prolapse and sexual disorders. however there are no studies in the literature that address the application of therapeutic resources available to improve the pfm awareness. the objective of this study is to evaluate the effectiveness of transvaginal electrical stimulation, vaginal palpation, vaginal palpation associated with posterior pelvic tilt and contraction of accessory muscles in the acquisition of ability to contract the pfm, as well as to evaluate the sexual function of women studied. one hundred twenty women with pfm function graded 0 and 1 measured by oxford modified scale will be submitted at random to physical therapy with transvaginal electrical stimulation, vaginal palpation, vaginal palpation associated with posterior pelvic tilt and contraction of accessory muscles (glutes and hip adductors) and the control group who receive verbal instructions related to the pelvic floor and its contraction. for the evaluation of the sexual function will be applied the female sexual function index (fsfi). the patients will be assessed by vaginal palpation, perineometry and surface electromyography before and after the intervention.

Eligibility criteria:
inclusion criteria: women with age greater than or equal 18 years; women with pelvic floor muscle function graded 0 and 1 measured by oxford modified scale; women who voluntarily consente to participate in research. exclusion criteria: women with associated neurological pathologies; women with symptoms of vaginal or urinary tract infection; women with pelvic organs prolapse graded greater than 2; pregnancy suspected or confirmed; cognitive deficit that impedes or impair the procedure.

Keywords: pelvic floor physical therapy specialty awareness electric stimulation palpation
characteristics of hypophosphatasia in adult patients in rheumatology

Conditions: Hypophosphatasia

Summary: with hypophosphatasia still being frequently overlooked and misdiagnosed, the primary aim of this prospective observational study is to determine the prevalence of hypophosphatasia in adult patients in rheumatology, and beyond that to establish an algorithm that promotes early hypophosphatasia detection in clinical practice.

hypophosphatasia (hpp) is a rare genetic disorder (1-3/300,000 severe cases in europe) caused by one or more mutations in the alkaline phosphatase (alp) gene. hypomineralization results in symptoms such as arthralgias, insufficiency fractures, and poor dental status beginning in childhood. a fatal outcome is conceivable in circumstances of early infancy first presentation. in consistency with the musculoskeletal complaint pattern, hpp is far more common in the rheumatology patient population than in the general population. however, hpp is still frequently misdiagnosed as some other form of bone disease (e.g., rickets, osteomalacia, or osteoporosis). therefore, implementation of a clinically applicable algorithm for early hypophosphatasia detection is needed. the primary aim of this prospective observational study is to determine the prevalence of hypophosphatasia in adult patients in rheumatology. moreover, a further goal is to establish an algorithm that reliably separates adult hpp patients from other, rheumatologic and bone diseases.

Eligibility criteria:
inclusion criteria: * written informed consent * age \> 18 years * clinical suspicion of hypophosphatasia * evidence of a pathological alp value within the clinical routine screening exclusion criteria: * failure to meet the inclusion criteria listed above

Keywords: hypophosphatasia hypophosphatasemia musculoskeletal complaints rare disease genetic disorder alkaline phosphatase gene alp alp gene rheumatic disease cohir study prevalence diagnostic algorithm metabolic bone diseases
tacrolimus ointment in oral lichen planus

Conditions: Oral Lichen Planus

Summary: the purpose of this study is to compare the effectiveness of topical tacrolimus, triamcinolone and placebo in alleviating signs and symptoms of oral lichen planus (olp).


Eligibility criteria:
inclusion criteria: * diagnosis of olp made by a specialist in oral pathology based on clinical and histopathological features * clinical score for olp ≥ 20 at baseline * symptomatic olp at baseline * washout period of 2 weeks * age over 18 exclusion criteria: * pregnant or lactating women * allergy to tacrolimus or other macrolides * allergy to other drugs or substances used in the study * abnormal liver function * netherton's syndrome * cyclosporin medication * other regular medication that could have significant interactions with tacrolimus

Keywords: oral lichen planus tacrolimus ointment triamcinolone paste
safety and efficacy of gsms-tace combined with surgical resection in the treatment of hepatocellular carcinoma (hcc) with type iii portal vein tumor thrombus (pvtt)

Conditions: Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)

Summary: a single center, open, randomized controlled trial evaluating the safety and efficacy of gsms-tace combined with surgical resection in the treatment of hepatocellular carcinoma (hcc) with type iii portal vein tumor thrombus (pvtt).


Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of hcc with pvtt involving the main portal vein, i.e. type iii pvtt according to cheng's classification. 2. confirmed abundant blood supply of tumor thrombus using computed tomography (ct) and magnetic resonance imaging (mri). 3. the tumor must be surgically resectable. 4. ecog performance status 0-2. 5. adequate liver function (child-pugh class a) 6. life expectancy ≥ 3 months 7. previous physical ablation is allowed. 8. age 18 to 75 years 9. able to sign and provide written informed consent. exclusion criteria: 1. patients previously took oral molecular targeted drug or received immunotherapy. 2. patients with arteriovenous fistula. 3. severe active infection \>grade 2 (except for hepatitis b and c infection). 4. concomitant malignant tumors in other organs. 5. presence of severe cardiac, lung or kidney disease. 6. pregnant or breast-feeding woman. 7. patients with severe neuropathy and unable to report therapeutic effects. 8. patients with severe atherosclerosis. 9. patients with aids. 10. severe hemorrhage of digestive tract within the 4 weeks prior to enrolment. 11. severe thrombogenesis or embolic event within the 6 months prior to enrolment. 12. currently enrolled or going to enroll in any other clinical trials. 13. subject is not suitable to participate in the study as judged by investigator (poor patient compliance, inability to follow up).
multislice computed tomography angiography in acute mesenteric ischemia

Conditions: Mesenteric Ischemia

Summary: acute mesenteric ischemia is a life-threatening condition with high mortality. acute mesenteric ischemia is responsible for fewer than one in 1000 hospital admissions, but its mortality rate ranges between 30% and 90% . acute mesenteric ischemia is most commonly secondary to embolism followed by arterial thrombosis, non-occlusive ischemia, and less commonly venous thrombosis . delay in diagnosis contributes to the continued high mortality rate. early diagnosis and prompt effective treatment are essential to correspondence to improve clinical outcomes

however, acute mesenteric ischemia represents a major diagnostic challenge because of its varied presentations and multiple causes . patients usually present with non-specific abdominal symptoms and laboratory findings, which leads to delayed diagnoses . therefore, diagnostic imaging has emerged as one of the most crucial components in the diagnostic work-up of suspected recent technical advances have made computed tomography angiography the modality of choice in the setting of suspected acute mesenteric ischemia.computed tomography angiography is a rapid and non-invasive diagnostic tool for assessing intestinal vasculature and bowel . computed tomography angiography allows early diagnosis and differentiation between occlusive and non-occlusive causes, which is important to direct therapeutic approach . overall, combining vascular and bowel assessment results in a high diagnostic accuracy . a recent meta-analysis showed a sensitivity of 93% and a specificity of 96% . however, this meta analysis also showed that the prevalence of confirmed .acute mesenteric ischemia is less than 25% among the patients referred to computed tomography angiograph in the setting of suspected acute mesenteric ischemia .knowledge of the prevalence and the demographic distribution of alternative diagnoses in the remaining three-fourths of patients without acute mesenteric ischemia is important for appropriate patient care. computed tomography angiograph is considered to allow for a variety of acute alternative diagnoses, ensuring timely triage of these patients.

Eligibility criteria:
inclusion criteria: clinically suspected acute mesenteric ischemia based on physician evaluation patients should be evaluated during 48 h of acute presentation exclusion criteria: * renal impairment * known allergy to iodine contrast media.
simultaneous administration study of varicella attenuated live vaccine and trivalent inactivated influenza vaccine (split virion)

Conditions: Varicella; Influenza Vaccine

Summary: the goal of this clinical trial is to evaluate the immunogenicity of simultaneous administration of varicella live attenuated vaccine (varicella vaccine hereafter) and trivalent inactivated influenza vaccine (tiv hereafter). it will also evaluate the safety of simultaneous administration of the two vaccines. the main questions it aims to answer are: * if geometric mean titer (gmt) of varicella zoster vrius (vzv) antibody in the simultaneous administration group is non-inferior to that in the varicella vaccine separate group. * if gmt of hemagglutination inhibition (hi hereafter) antibody in the simultaneous administration group is non-inferior to that in the tiv separate group. participants in the simultaneous administration group received a single dose of varicella vaccine and tiv simultaneously on day 0. participants in the separate groups received a single dose of varicella vaccine or tiv on day 0, respectively.


Eligibility criteria:
inclusion criteria: * healthy children aged 7-12 years; * the subject or legal guardian can understand and sign the informed consent form (double signature is required for those over 8 years old); * participants and their legal guardians voluntarily participate in the study and are able to comply with all study procedures; * provide legal identity proof; exclusion criteria: * vaccination history of varicella vaccine; * had received a single dose of influenza vaccine for 2024-2025 season; * history of varicella; * history of severe allergic reactions to vaccines (such as acute anaphylaxis, angioedema, dyspnea, etc.); * suffering from acute disease, severe chronic disease, acute exacerbation of chronic disease; * with any confirmed or suspected immunodeficiency disease, immunocompromised or receiving immunosuppressive therapy (including systemic steroid therapy); * with a history of congenital immune diseases or close contact with family members with a history of congenital immune diseases; * with encephalopathy, uncontrolled epilepsy, other progressive neurological disorders, history of guillain-barre syndrome; * body temperature \>37℃ at the time of vaccination; * receipt of blood products within 3 months before receiving investigational vaccine; * receipt of another study drug within 30 days before receipt of the investigational vaccine; * receipt of live attenuated vaccine within 28 days before receipt of investigational vaccine; * receipt of subunit or inactivated vaccine within 7 days before receipt of investigational vaccine; * participated in other clinical trials before enrollment and were enrolled in another clinical trial during the follow-up period or planned to participate in another clinical trial within 3 months; * the participant had any other factors that were ineligible for vaccination by in the investigator's judgment.
n-acetylcysteine in severe acute alcoholic hepatitis

Conditions: Alcoholic Hepatitis

Summary: acute alcoholic hepatitis (aah) is the most severe form of alcoholic liver disease (ald) and is associated with a high risk of dying in the short term. corticosteroids are generally recommended in patients with severe aah, but its use is still controverted and contraindicated in case of active infection or gastrointestinal bleeding. therefore, alternative therapeutic options are needed.ethanol consumption results in the depletion of endogenous antioxidant capabilities and patients with ald have evidence of antioxidant deficiencies.due to its effects on glutathion stores restoration and as such the limitation of the oxidative stress and its good tolerance and safety profile, n-acetylcysteine (nac) is an attractive agent for the treatment of aah.in this context, we hypothesized that nac might be beneficial in severe aah.


Eligibility criteria:
inclusion criteria: * biopsy proven alcoholic hepatitis * severe disease defined by a maddrey score superior to 32 exclusion criteria: * neoplastic disease compromising 6 months survival * hiv patients * hepatorenal syndrome

Keywords: alcoholic hepatitis n-acetylcysteine enteral nutrition oxidative stress severe acute alcoholic hepatitis
bone pain score validation initiative

Conditions: Bone Metastasis

Summary: translation and validation of the bomet-qol-10 questionnaire in germany and assessment of its validity and responsiveness.

aim of this study is to translate the questionnaire and to examine the psychometric properties of bomet-qol-10 in a german population. correlations with the eortc qlq-c30/bm22 at the time of enrolment and throughout the study aim to verify that the bomet-qol-10 is reliable, valid and able to detect stabilization or changes in quality of life.

Eligibility criteria:
inclusion criteria: * male or female adults patients (≥ 18 years) * diagnosed cancer of the breast, kidney, lung or prostate * bone metastases * estimated life expectancy of at least 6 months * fluent german speaking, reading and writing * informed written consent exclusion criteria: * patients without bone metastases * participation in another study involving questionnaires * patients not able to comply with the assessments specified in the protocol

Keywords: primary cancers of the breast primary cancers of the kidney primary cancers of the lung primary cancers of the prostate
pediatric urology recovery after surgery endeavor (pursue)

Conditions: Urologic Surgical Procedures; Urinary Bladder, Neurogenic; Urinary Bladder Diseases

Summary: the purpose of this research study is to evaluate an enhanced recovery after surgery (eras) protocol in children and young adults undergoing urologic reconstructive surgery. the investigators plan to collect data on speed of recovery (how quickly pain improves, length of time in the hospital, and the need for additional pain control) on patients who receive care under the eras protocol and compare it to historical controls.

the purpose of this project is to evaluate enhanced recovery after surgery (eras) in the pediatric setting for participants undergoing intraabdominal urologic reconstruction procedures. eras practices are being implemented in the department independent of research and this project will allow the investigators to review these practices. providers, participants, and family members will complete pre- and post- surgery questionnaires. these questionnaires are geared to collect demographic information about the participant and how the surgery affects their life situation. the providers will answer questions regarding their experience with eras. evidence-based eras principles and procedures are compulsory components of this project. these will be documented in the medical record and are considered standard of care practice as part of perioperative patient care. data collected from the medical record for each participant will aid in evaluating if adherence to the eras protocol is achieved.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 4 or \<26 years at time of surgery * undergoing urologic reconstructive surgery that includes primary bowel anastomosis (i.e., creation of continent ileovesicostomy \[monti\], sigmoid monti channel, enterocystoplasty) * undergoing urologic reconstructive surgery that includes possible bowel anastomosis (planned creation of continent appendicovesicostomy \[mitrofanoff\] with inability to use appendix at time of surgery and creation of alternative channel requiring primary bowel anastomosis) exclusion criteria: • clinically constipated (defined as bristol 1 or 2 stools more than once per week, bowel movement interval \> every other day \[e.g. only has bowel movement every 3 days, or palpable stool in \> 50% of colon on physical preoperative exam)

Keywords: enhanced recovery after surgery urologic reconstruction pediatric urology bladder augmentation mitrofanoff malone antegrade continence enema channel appendicovesicostomy ileovesicostomy appendicocecostomy
a study of lifestyle intervention in overweight or obese women with early stage breast cancer

Conditions: Weight

Summary: the purpose of this study is to test the hypothesis that an intervention of lifestyle modification will positively impact women with breast cancer who are overweight and/or obese. to that end, our primary endpoint is to examine the effects of a practical lifestyle intervention that can be implemented by overweight or obese women (bmi greater or equal to 25) with early stage breast cancer (i-iii) on outcomes such as body weight and change in bmi over the course of the study.

* primary endpoint: to examine the effects of a practical lifestyle intervention that can be implemented by overweight or obese women (bmi greater or equal to 25) with early stage breast cancer (i-iii) on outcomes such as body weight and change in bmi over the course of the study. * secondary endpoint: to assess the impact of such intervention on lipid profiles and hemoglobin a1c. the study group will be compared with a historical control group of patients with early stage breast cancer who are obese or overweight who were not given the intervention * secondary endpoint: to examine whether an active intervention program will lead into longstanding lifestyle modification in breast cancer patients with a bmi greater or equal to 25.

Eligibility criteria:
inclusion criteria: * dcis * women with stage 0 - iii breast cancer (histologic type ductal or lobular) * bmi \>=25 * patients must have completed all chemotherapy * patients may be on hormonal therapy or radiation therapy * age \>= 18 years old to 89 years old * patient must be medically stable and without significant impairments that would preclude following the proposed intervention regimen. * time of diagnosis: patients enrolled are within 1 month to 18 months post-diagnosis. exclusion criteria: * metastatic breast cancer patients and patients with inoperable or active loco-regional disease. * patients following alternative/complementary diets or taking high dose antioxidant supplements. * patients with a physical/psychiatric impairment that would seriously impair their physical mobility. * patients who are currently suffering from severe nausea, anorexia or other diseases affecting health (e.g. arthritis and multiple sclerosis). * patients younger than 18 and older than 89 years.

Keywords: bmi, lipid profile